Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
I guess it’s for all of us to decide whether to be a member of the “nothing concrete” club - or believe in the credibility & superior knowledge of posters who understand the science and underpinning processes.
Now, let me see………..
We also recently discussed on here the words Lindy used in the Interims Presentation, relating to Genmab taking SC129 into the clinic. Open to individual interpretation of course but those words did appear bullish and that it WAS being taking into the clinic by Genmab.
It would be fascinating to know how SCOPE recruitment is going.
From the Interims:
Second stage of SCOPE study in advanced melanoma with SCIB1 anticipated to complete recruitment in Q1 2024 with data available in Q3 2024.
· iSCIB1+ cohort of the SCOPE study to start recruitment in Q1 2024 with clinical data expected in Q3 2024.
Yes, Q3 is still some way off but the end of Q1 really isn’t that far away now.
New ISA year also approaching. I wonder if that might be on PI’s minds, given the upbeat Interims and published timelines. It’s on mine :-)
HAGW
The Betamax/VHS analogy wasn’t intended to provoke such deep analysis. Of course it’s not the same as medicine - that is bloomin obvious!
The point is a high-level one. What some folks strongly believe is the future, doesn’t always turn out to be the case.
Anyway, enough of these analogies. I have an appointment to get to, so it’s on with the Google Glasses and fire up the DeLorean.
CW - stripping out all the “big picture” waffle, earlier you posted that you hoped the need to attend big conferences like ASCO & AACR would diminish.
When I said that wouldn’t happen and they would continue to attend, even as the Company grows, you agreed with me.
Thanks for making your change of mind clear.
CW - “ Hopefully there time to impress and excplaining ground breaking , trailblazing , scientific in scientific posters, in large halls is diminishing !” (Said with reference to AACR & ASCO).
You really think that if Scancell were a multi-billion company in the future, they would not want or feel the need to attend these industry leading conferences??
Bojo- historic posts from CW with clear hostility towards Crumbs & Bermuda were also “very well put together”? Maybe you’ve forgotten those.
Btw - I’ve no issues with the 8:48 either.
Hey Burble.
Ciaskin kindly pasted a link yesterday.
https://vimeo.com/907889586/5d861ac47d?share=copy
Didn’t Lindy confirm in the presentation that Genmab WERE taking SC129 into the clinic and WERE very happy with it (or bullish words to that effect)?
I seem to recall that Berm (apols if not correct Berm), indicated some time back that that point in time, would typically be a development milestone to trigger a further payment in accordance with the type of deal in place.
Of course we don’t know how much that would be, nor precisely when it would be paid but given what Lindy said in the presentation, surely it’s reasonable to expect that payment to be made in the near term?
If that is confirmed via RNS inside the next couple of months, maybe the market will wake up to the commercial prospects here.
I can see that at the link below, it was last reviewed yesterday. Not sure if that means just reviewed (perhaps in connection with the presentation) and nothing updated, or something has been changed, or added?
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-SCIB1-pembrolizumab-advanced-melanoma#undefined